ClinicalTrials.gg
RecruitingNCT07224321INHALE-1stUpdated Aug 13, 2026

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

A Phase 2 interventional study of Technosphere Insulin and Technosphere Insulin in Type 1 Diabetes Mellitus, sponsored by Mannkind Corporation. Recruiting at 10 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Mannkind Corporation · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 — 1 open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 1.

Planned enrollment
17th of 35
100 · median 74
Started
2026
the only one that year
Phase 2
8 of 35
1 open now
Registered
35th of 35
by date
Lead sponsor
14 of 35
Mannkind Corporation

Among the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, this one is the 17th largest by planned enrollment, is the only one that started in 2026, is one of 8 in phase 2, and was the 35th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

1 of the 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1 is open now, in 1 country.

By country, each count listing its studies:

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 412 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 258 (63%) stop at 75 or younger; 185 take children under 18; 64 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

INHALE-1st is a Phase 2, single-arm, multi-center, clinical study evaluating the safety and efficacy of Afrezza in combination with subcutaneously-injected basal insulin (BI) for youth 6 to \<18 years old with newly diagnosed stage 3 type 1 diabetes (T1D). The study will also evaluate the effect of an Afrezza plus BI reigmen on participant and parent/legally authorized representative satisfaction. Participants will be followed for 13 weeks during the main phase followed by an optional Extension Phase for participants continuing to use Afrezza in combination with BI for up to 26 weeks.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Diabetes Mellitus
  • Insulin
  • Inhaled
  • Afrezza
  • Technosphere
  • Pediatric
  • Inhaled Insulin
  • Type 1 Diabetes
  • Newly diagnosed type 1 diabetes
  • Technosphere Insulin
  • rapid-acting inhaled insulin
  • Meal-time inhaled insulin
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 6 to \<18 years of age
  • Clinical diagnosis of stage 3 T1D, per the investigator. Stage 3 is defined as hyperglycemia, meeting ADA glycemic and clinical diagnostic criteria
  • Able to start the Afrezza-BI regimen within 21 days following T1D diagnosis (day 1 is based on the first insulin dose)
  • (FEV1) >80.0% of predicted Global Lung Function Initiative (GLI) value
  • Investigator believes that participant can be expected to follow the study protocol
  • No medical, psychiatric, psychosocial conditions, or medications being taken that in the investigator's judgment would be a safety concern for participation in the study

Exclusion criteria

Exclusion Criteria:

  • Prior insulin treatment for stage 2 T1D
  • In the judgment of the investigator, history of chronic lung disease, such as asthma, or , lung cancer, or any other pulmonary disease (e.g., cystic fibrosis, bronchopulmonary dysplasia)
  • Allergy or known to human regular insulin
  • Smoking (includes cigarettes, cigars, pipes, marijuana, and vaping devices) within 3 months prior to screening and/or positive cotinine test for smoking
  • Positive urine pregnancy test for female subjects of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Afrezza (Technosphere Insulin) + Basal Insulin

    Individualized dose of Afrezza (Technosphere Insulin) and basal insulin for each patient before each meal (breakfast, lunch, and dinner) for 13 weeks.

    Drug: Technosphere Insulin · Drug: Basal insulin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants with Continuous Glucose Meter (CGM) measured time in range (TIR) ≥70%

    Percentage of participants with a CGM-measured TIR 70-180 mg/dL ≥70% during 14 days prior to 13-week visit

    Time frame: 13 weeks

Secondary outcomes

  1. Mean Continuous Glucose Monitoring (CGM) glucose

    Mean CGM glucose from baseline to 13 weeks

    Time frame: 13 weeks

  2. Continuous Glucose Monitoring (CGM) measured time-in-tight-range 70-140 mg/dL

    Continuous Glucose Monitoring (CGM) measured time-in-tight-range 70-140 mg/dL from baseline to 13 weeks

    Time frame: 13 weeks

  3. Continuous Glucose Monitoring (CGM) measured percent time with glucose greater than 180 mg/dL

    CGM-measured percent time with glucose \> 180 mg/dL from baseline to 13 weeks

    Time frame: 13 weeks

  4. Continuous Glucose Monitoring (CGM) measured time with glucose greater than 250 mg/dL

    Continuous Glucose Monitoring (CGM) measured time with glucose greater than 250 mg/dL from baseline to 13 weeks

    Time frame: 13 weeks

  5. Continuous Glucose Monitoring (CGM) measured time with glucose less than 70 mg/dL

    Continuous Glucose Monitoring (CGM) measured time with glucose less than 70 mg/dL from baseline to 13 weeks

    Time frame: 13 weeks

  6. Continuous Glucose Monitoring (CGM) measured time with glucose less than 54 mg/dL

    Continuous Glucose Monitoring (CGM) measured time with glucose less than 54 mg/dL from baseline to 13 weeks

    Time frame: 13 weeks

  7. Continuous Glucose Monitoring (CGM) measured coefficient of variation

    CGM-measured coefficient of variation from baseline to 13 weeks

    Time frame: 13 weeks

  8. Change in glycated hemoglobin (HbA1c)

    Change in HbA1c from baseline to 13 weeks

    Time frame: 13 weeks

  9. Patient Reported Outcome: Insulin Treatment Satisfaction Questionnaire (ITSQ), Caregiver

    Patient-reported outcome (PRO) survey for Insulin Treatment Satisfaction Questionnaire (ITSQ), customized for the study. Inconvenience subscale (items 1-3,15,16; now listed as 1-5) and Delivery System subscale (items 17-22; now listed as 6-11) and one additional item added by study team (#12). Higher scores indicate less treatment satisfaction.

    Time frame: 13 weeks

  10. Patient Reported Outcome: Insulin Treatment Satisfaction Questionnaire (ITSQ), Participant

    Patient-reported outcome (PRO) survey for Insulin Treatment Satisfaction Questionnaire (ITSQ), customized for the study. Inconvenience subscale (items 1-3,15,16) and Delivery System subscale (items 17-22). Higher scores indicate less treatment satisfaction.

    Time frame: 13 weeks

  11. Patient Reported Outcome: Insulin Treatment Satisfaction Questionnaire (ITSQ), Caregiver

    Patient-reported outcome (PRO) survey for Insulin Treatment Satisfaction Questionnaire (ITSQ), customized for the study. Inconvenience subscale (items 1-3,15,16; now listed as 1-5) and Delivery System subscale (items 17-22; now listed as 6-11) and one additional item added by study team (#12) Higher scores indicate less treatment satisfaction.

    Time frame: 39 weeks

  12. Patient Reported Outcome: Insulin Treatment Satisfaction Questionnaire (ITSQ), Participant

    Patient-reported outcome (PRO) survey for Insulin Treatment Satisfaction Questionnaire (ITSQ), customized for the study. Inconvenience subscale (items 1-3,15,16) and Delivery System subscale (items 17-22) Higher scores indicate less treatment satisfaction.

    Time frame: 39 weeks

  13. Percentage of participants using Afrezza and basal insulin (Afrezza-BI) regimen

    Percentage of participants using Afrezza-BI regimen at time of 13-week visit

    Time frame: At 13 weeks

  14. Percentage of participants that continue on the Afrezza and basal insulin (Afrezza-BI) regimen

    Percentage of participants that continue on Afrezza-BI after 13-week visit

    Time frame: After 13 weeks

  15. Incidence of Adverse Events of Special Interest (AESIs)

    Incidence and severity of AESIs which include the following events: acute bronchospasm, clinically relevant decline in pulmonary function (\>15% decline from baseline percent predicted FEV1 accompanied by respiratory symptoms), hypersensitivity reactions, including anaphylaxis, hospitalization for asthma, use of corticosteroid bursts for diagnosis of asthma, diagnosis of asthma, diabetic ketoacidosis, severe hypoglycemia

    Time frame: 13 weeks

  16. Incidence of Adverse Events of Special Interest (AESIs)

    Incidence and severity of AESIs which include the following events: acute bronchospasm, clinically relevant decline in pulmonary function (\>15% decline from baseline percent predicted FEV1 accompanied by respiratory symptoms), hypersensitivity reactions, including anaphylaxis, hospitalization for asthma, use of corticosteroid bursts for diagnosis of asthma, diagnosis of asthma, diabetic ketoacidosis, severe hypoglycemia

    Time frame: 39 weeks

  17. Change in percent predicted FEV1

    Change in percent predicted FEV1 from baseline to Week 13

    Time frame: 13 weeks

  18. Change in percent predicted FEV1

    Change in percent predicted FEV1 from baseline to Week 39

    Time frame: 39 weeks

  19. Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Incidence and severity of TEAEs and SAEs

    Time frame: 13 weeks

  20. Incidence and severity of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Incidence and severity of TEAEs and SAEs

    Time frame: 39 weeks

07

Study locations

10 of 10 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2027, 13 months after the start.

Of 50 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 33. This study's planned 13 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2025
First posted
Nov 4, 2025
StartActual
Feb 4, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07224321
Responsible party
Sponsor
First posted
Nov 4, 2025
Start date
Feb 4, 2026
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Jennifer Pleitez
Contact
jpleitez@mannkindcorp.com
818-661-5032

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion